Gilton Javier Jimenez Quezada.
Hi i here jimenez i’m going to talk about canalifusing and renal outcomes in type 2 diabetes and nephropathy definition cannabis belongs to a group of new oral anti-diabetic that exerts their action by inhibiting the sodium glucose co-transporters type 2 it is used along or in combination with another hypoglycemic agent so the last one we looked at today was
Canoglyphilism for the treatment of type 2 diabetes this is a completely novel drug that causes glucose urea causes glucose in the urine to be excreted so that patients excrete calories basically in their urine and this is the mechanism of action it’s unlike any uh prior therapy for type 2 diabetes you know the biggest difference here is its effect on weight
Because calories literally come out in the urine so some of the calories that patients ingest don’t even end up contributing to their weight that come out of the urine it causes the most weight loss at any of the drugs available for type 2 diabetes and this is the big difference really compared with existing treatments it is safe in the short-term studies that
Allowed it to be approved by the fda it does not cause hypoglycemia in monotherapy it causes about the same degree of a1c reduction as other treatments for type 2 diabetes but causes significantly more weight loss in fact some of the other drugs actually cause weight gain when they’re taken for diabetes there’s two safety issues the side effect is kind of an
Unusual one because glucose appears in the urine there’s an increased risk of fungal infections fungal melanitis for men and vaginal candidizes for women and probably simply relates to the milieu of the extra sugar in the urine being sort of a a petri dish for candid infections to develop those are generally you know not serious and treatable the one long-term
Issue which hasn’t been completely addressed yet is whether it might be related to increased risk for certain types of cancers so the fda has required post-marketing surveillance for this drug to see if in fact that is the case they did not think that was likely enough that it was a barrier to improving the drug obligation in medicine in disabled being random
Maestro we achieved patient with type 2 diabetics angle bulimia chronic kidney disease to receive cannabis ocean other dose of 100 milligrams daily or the sebu all the patient had an estimated glomerular filtration rate and albuminuria and we’re treated with renin-angiotensin system located health matters is the informational webcast brought to you by netmeds
Designed to keep you informed and up to date on popular medicines emerging therapies and even cutting-edge strategies for enhanced wellness less sickness and greater energy this medicine contains canagliflozin which works together to control blood sugar levels in adult patients with the form of diabetes called type 2 diabetes mellitus it helps to lower the
Amount of sugar made by your body it can be used alone or in combination with certain other medicines that lower the blood sugar level talk to your doctor before taking this medicine if you have type 1 diabetes or ketone bodies in urine or if you have kidney liver heart problems and stroke consult your doctor if you are pregnant or planning to be pregnant or
Are breastfeeding before taking this medicine pros and cons from the drive was stopped early after a plane entering analysis on the recommendation of the data and safety monitoring commit because this mechanism is different than previous long-term treatment of type 2 diabetes mellitus the creighton’s trial was a trial that was designed to study canicaflozin
Which is a drug that people with diabetes take to lower the blood sugar and we wanted to evaluate if canigaflozin improved kidney function in people who have type 2 diabetes and have kidney disease with it credence showed that canigaflozin reduced the progression to kidney failure by 30 percent compared to placebo importantly it also reduced cardiac death and
Hospitalizations for heart failure by 31 this finding is really really important because it is the first drug in 20 years that shows that you can improve kidney outcomes and the progression to renal failure or kidney failure and hemodialysis in people with type 2 diabetes issue of lighting a quarter in the province of rios the incident is higher but still does
Not reveal figures because the study does not to end esmeraldas will be the next province in which area with its work teams will focus its research this trial is really important because diabetes and diabetic kidney disease are 21st century epidemics there are more than 400 million people with diabetes around the world at the moment and 40 of these people will
Get kidney disease once they’ve got kidney disease they’re at very high risk of kidney failure of heart attack of stroke of heart failure and of death people with diabetes who develop kidney disease have at the moment few treatments proven to be beneficial in terms of preventing kidney failure only one class of blood pressure lowering agents has been proven to
Be beneficial and that was confirmed some 18 years ago in the time in between we’ve had no new treatments for this vastly important problem so with this trial we took a drug that’s available today for lowering blood sugar levels in people with diabetes but which we thought may well have additional special beneficial effects for the kidney and we gave it to people
With diabetes who already had evidence of kidney damage mostly through the presence of protein in the urine we took four thousand four hundred and one of these people from over thirty countries around the world and we gave half of them this drug cannibalism and the other half an identical placebo and we followed these people for an average of two and a half years
To see what happened to them we found a very dramatic result we found that people who received this treatment had a 30 lower risk of kidney failure and related events they also had a lower risk of cardiovascular events like heart attack stroke or death from cardiovascular causes and a dramatically lower risk of heart failure all really big problems in people with
Diabetes and kidney disease conclusion in patients with type 2 diabetes and kidney disease the risk of kidney failure and cardiovascular events was lower in the canality group than in the placebo group at the median follow-up of 2.62 years type 2 diabetes can lead to a number of complications including kidney disease healthy kidneys play an important role removing
Waste products from the blood inside the kidneys millions of tiny blood vessels act as filters many substances are too big to pass through the filters so remain in the bloodstream while smaller substances including some waste products flow through the filters and become part of the urine kidney function helps to regulate the amount of fluids and salts in the body
And control blood pressure but with type 2 diabetes the high levels of sugar circulating in the blood can damage the kidneys and compromise their function approximately 40 percent of patients with type 2 diabetes have established kidney disease patients begin to lose their kidney function including their ability to filter out waste medicines and excess fluids from
The body the presence of protein in the urine can be an early sign of kidney disease symptoms of kidney disease may include swelling due to fluid retention tiredness insomnia itchy skin and nausea kidney disease progresses through different stages as the kidneys lose efficiency and waste materials build up in the body it also increases the risk of hypoglycemia
And type 2 diabetes complications including cardiovascular disease the last stage kidney failure usually requires treatment with dialysis or kidney transplantation many of the medications available to treat type 2 diabetes are predominantly removed from the body by the kidneys declining kidney function can affect that process if the body can no longer filter
Medications out effectively the risk of side effects may increase it may also be necessary to adjust the dose of medication or change medications you
Transcribed from video
Canagliflozin and Renal Outcomes in Type Diabetes and Nephropathy. By Javier Jimenez